New job, new agency, new challenges
This article was originally published in Scrip
Executive Summary
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has a new chief executive. Ian Hudson, who succeeds Professor Sir Kent Woods, takes over the running of an agency that bears little resemblance to the one he joined in 2001 as director of the licensing division, two years before the Medicines Control Agency merged with the Medical Devices Agency.
You may also be interested in...
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
EU Plans IP Law Shake-Up
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Need a specific report? 1000+ reports available
Buy Reports